- Home
- GNLX vs BCIC Comparison
GNLX vs BCIC Comparison
Compare GNLX & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNLX | BCIC |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 96.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNLX | BCIC |
|---|---|---|
| Price | $2.88 | $8.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $17.25 | $9.00 |
| AVG Volume (30 Days) | ★ 152.2K | 85.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 14.14% |
| EPS Growth | ★ 9.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | $0.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.29 | $7.11 |
| 52 Week High | $8.54 | $13.50 |
Technical Indicators
Market Signals| Indicator | GNLX | BCIC |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 52.75 |
| Support Level | $2.36 | $7.75 |
| Resistance Level | $2.97 | $8.21 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 52.64 | 66.67 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About BCIC BCP Investment Corporation
BCP Investment Corp is an externally managed, non-diversified closed-end investment company. The company invests in secured term loans, bonds or notes and mezzanine debt in privately-held middle market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt and selected equity investments in privately-held middle market companies.